About Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial
Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial (GATD3) is a protein
from Homo sapiens identified by UniProt accession
P0DPI2, 268 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial |
|---|
| UniProt accession | P0DPI2 |
|---|
| Gene | GATD3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 268 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (26)
Diseases linked to this target (Open Targets).
- inflammatory bowel disease · score 0.18
- Crohn's disease · score 0.18
- ulcerative colitis · score 0.18
- ankylosing spondylitis · score 0.14
- sclerosing cholangitis · score 0.12
- psoriasis · score 0.12
- type 1 diabetes mellitus · score 0.06
- body fat percentage · score 0.02
- diet measurement · score 0.02
- colorectal adenocarcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P0DPI2-F1 | alphafold | PREDICTED | 90.48 | — |
Amino-acid sequence (268 residues)
MAAVRVLVAS RLAAASAFTS LSPGGRTPSQ RAALHLSVPR PAARVALVLS GCGVYDGTEI HEASAILVHL SRGGAEVQIF APDVPQMHVI DHTKGQPSEG ESRNVLTESA RIARGKITDL ANLSAANHDA AIFPGGFGAA KNLSTFAVDG KDCKVNKEVE RVLKEFHQAG KPIGLCCIAP VLAAKVLRGV EVTVGHEQEE GGKWPYAGTA EAIKALGAKH CVKEVVEAHV DQKNKVVTTP AFMCETALHY IHDGIGAMVR KVLELTGK
Explore Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets